LEDDEGIGT – - Sundhedsstyrelsen

Litteratur
1 Bath J, Hooper J, Giles
M, Steel D, Reed E,
Woodland J.
Patient perceptions of
rheumatoid arthritis.
Nurs Stand 1999;
14(3):35-38.
2 Lorig K.
Patient education:
treatment or nice extra.
Br J Rheumatol 1995;
34(8):703-704.
3 Belza BL, Henke CJ,
Yelin EH, Epstein WV,
Gilliss CL.
Correlates of fatigue in
older adults with
rheumatoid arthritis.
Nurs Res 1993; 42(2):93-
99.
4 Belza BL. Comparison
of self-reported fatigue
in rheumatoid arthritis
and controls. J
Rheumatol 1995;
22(4):639-643.
5 Koike T.
The relationship between
fatigue, coping
behavior and inflammation
in patients with
rheumatoid arthritis.
Mod Rheumatol 2000;
10:141-149.
6 Tiesinga LJ, Dassen TW,
Halfens RJ, van den
Heuvel WJ.
Factors related to fatigue;
priority of interventions
to reduce or
eliminate fatigue and
the exploration of a
multidisciplinary research
model for further
study of fatigue.
Int J Nurs Stud 1999;
36(4):265-280.
7 Strand V, Cohen S,
Schiff M, Weaver A,
Fleischmann R, Cannon
G et al.
Treatment of active
rheumatoid arthritis
with leflunomide compared
with placebo and
methotrexate. Le-flunomide
Rheumatoid
Arthritis Investigators
Group. Arch Intern Med
1999; 159(21):2542-2550.
8 Smolen JS, Kalden JR,
Scott DL, Rozman B,
Kvien TK, Larsen A et al.
Efficacy and safety of
leflunomide compared
with placebo and sulphasalazine
in active
rheumatoid arthritis: a
double-blind, randomised,
multicentre trial.
European Leflunomide
Study Group. Lancet
1999; 353(9149):259-266.
9 Weinblatt ME, Coblyn
JS, Fox DA, Fraser PA,
Holdsworth DE, Glass
DN et al.
Efficacy of low-dose
methotrexate in
rheumatoid arthritis. N
Engl J Med 1985;
312(13):818-822.
10 Maini R, St Clair EW,
Breedveld F, Furst D, Kalden
J, Weisman M et al.
Infliximab (chi-meric
anti-tumour necrosis
factor alpha monoclonal
antibody) versus
placebo in rheumatoid
arthritis patients receiving
concomitant
methotrexate: a randomised
phase III trial.
ATTRACT Study Group.
Lancet 1999;
354(9194):1932-1939.
11 Weinblatt ME, Kremer
JM, Bankhurst AD,
Bulpitt KJ, Fleischmann
RM, Fox RI et al.
A trial of etanercept, a
recombinant tumor
necrosis factor receptor:
Fc fusion protein, in patients
with rheumatoid
arthritis receiving
methotrexate. N Engl J
Med 1999; 340(4):253-259.
12 Elliott MJ, Maini RN,
Feldmann M, Kalden JR,
Antoni C, Smolen JS et al.
Randomised doubleblind
comparison of
chimeric monoclonal
antibody to tumour
necrosis factor alpha
(cA2) versus placebo in
rheumatoid arthritis.
Lancet 1994;
344(8930):1105-1110.
13 Moreland LW,
Baumgartner SW, Schiff
MH, Tindall EA,
Fleischmann RM,
Weaver AL et al.
Treatment of rheumatoid
arthritis with a recombinant
human tumor
necrosis factor receptor
(p75)-Fc fusion
protein. N Engl J Med
1997; 337(3):141-147.
14 Moreland LW, Schiff
MH, Baumgartner SW,
Tindall EA, Fleischmann
RM, Bulpitt KJ et al.
Etanercept therapy in
rheumatoid arthritis. A
randomized, controlled
trial. Ann Intern Med
1999; 130(6):478-486.
15 Tugwell P, Wells G,
Strand V, Maetzel A,
Bombardier C, Crawford
B et al.
Clinical improvement
as reflected in measures
of function and
health-related quality
of life following treatment
with leflunomide
compared with methotrexate
in patients with
rheumatoid arthritis: sensitivity
and relative efficiency
to detect a treatment
effect in a twelvemonth,
placebo-controlled
trial. Leflunomide
Rheumatoid Arthritis
Investigators Group.
Arthritis Rheum 2000;
43(3):506-514.
16 Strand V, Cohen S,
Schiff M, Weaver A,
Fleischmann R, Cannon
G et al.
Treatment of active
rheumatoid arthritis
with leflunomide compared
with placebo and
methotrexate. Leflunomide
Rheumatoid
Arthritis Investigators
Group. Arch Intern Med
1999; 159(21):2542-2550.
17 Strand V, Tugwell P,
Bombardier C, Maetzel
A, Crawford B, Dorrier
C et al.
Function and health-related
quality of life: results
from a randomized
controlled trial of
leflunomide versus
methotrexate or placebo
in patients with active
rheumatoid arthritis.
Leflunomide
Rheumatoid Arthritis
Investigators Group.
Arthritis Rheum 1999;
42(9):1870-1878.
18 Lipsky PE, van der
Heijde DM, St Clair EW,
Furst DE, Breedveld FC,
Kalden JR et al.
Infliximab and methotrexate
in the treatment
of rheumatoid arthritis.
Anti-Tumor Necrosis
Factor Trial in
Rheumatoid Arthritis
with Concomitant
Therapy Study Group.
N Engl J Med 2000;
343(22):1594-1602.
19 Poulsen A.
Psychodynamic, timelimited
group therapy
in rheumatic disease – a
controlled study with
special reference to
alexithymia. Psychother
Psychosom 1991; 56(1-
2):12-23.
20 Buchi S, Sensky T, Allard
S, Stoll T, Schnyder U,
Klaghofer R et al.
Sense of coherence – a
protective factor for
depression in rheumatoid
arthritis. J
Rheumatol 1998;
25(5):869-875.
21 Barsky AJ, Orav EJ,
Ahern DK, Rogers MP,
Gruen SD, Liang MH.
Somatic style and
symptom reporting in
rheumatoid arthritis.
Psychosomatics 1999;
40(5):396-403.
22 Riemsma RP, Taal E,
Wiegman O, Rasker JJ,
Bruyn GAW, Van
Paassen HC.
Problematic and positive
support in relation
to depression in people
with rheumatoid arthritis.
J Health Psychol
2000; 5(2):221-230.
23 Gigtforeningen.
Et liv med leddegigt.
Gigtforeningens store
undersøgelse af 1800
leddegigtpatienters
holdninger og dagligdag
med leddegigt.
København:
Gigtforeningen, 2000.
24 Bekendtgørelse af lov
om dagpenge ved sygdom
eller fødsel
(LBK nr.147 af
02/03/2001).
København: Socialministeriet,
2001.
25 Bekendtgørelse af lov
om social pension
(LBK nr 615 af
26/06/2001).
København: Socialministeriet,
2001.
26 Bekendtgørelse af lov
om aktiv socialpolitik
(LBK nr 614 af
26/06/2001).
København: Socialministeriet,
2001.
27 Tilkendelser af førtidspension
til ansøgere
uden pension fordelt på
diagnose og afgørelse,
1997, 1999 og 2000.
Registerudtræk, august
2001. København: Den
Sociale Ankestyrelse,
Analysekontoret, 2001.
28 Metode til god sagsbehandling
på førtidspensionsområdet.
1. udgave. København:
Socialministeriet, 2000.
98 LEDDEGIGT – medicinsk teknologivurdering af diagnostik og behandling
LEDDEGIGT – medicinsk teknologivurdering af diagnostik og behandling 99